Accéder au contenu
Merck

T4680

Terazosin hydrochloride

≥98% (TLC), α1-adrenoceptor antagonist, powder

Synonyme(s) :

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C19H25N5O4 · HCl
Numéro CAS:
63074-08-8
Poids moléculaire :
423.89
UNSPSC Code:
12352200
PubChem Substance ID:
24278740
NACRES:
NA.77
MDL number:
MFCD00467965
Assay:
≥98% (TLC)
Form:
powder
Quality level:
200

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Terazosin hydrochloride, ≥98% (TLC), powder

Quality Level

200

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H2O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow, methanol: 20 mg/mL, clear, colorless, ethanol: 4 mg/mL

originator

Abbott

SMILES string

Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H

InChI key

IWSWDOUXSCRCKW-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Catégories apparentées

General description

Terazosin hydrochloride is used to treat hypertension and benign prostatic hyperplasia (BPH). It is metabolised in the liver. It might be associated with dizziness, headache and asthenia. Terazosin hydrochloride is linked to acute generalized exanthematous pustulosis.

Application

Terazosin hydrochloride has been used for orthogonality and similarity analysis using reversed-phase chromatographic studies5. Furthermore, terazosin has also been used for the evaluation of chemometric techniques to determine orthogonality and similarity in chromatographic methods6.

Biochem/physiol Actions

α1-adrenoceptor antagonist.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Terazosin hydrochloride is soluble in water at 19.60 - 20.40 mg/ml and yields a clear, colorless to faint yellow solution. It is also soluble in ethanol at 4 mg/ml. Furthermore, the product is soluble in methanol at 20 mg/ml, with heat as needed, and yields a clear, colorless solution.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000453616
0000453615
0000453616
0000453615
0000432990

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Terazosin in the treatment of benign prostatic hyperplasia
Brawer MK, et al.
Archives of Family Medicine, 2(9), 929-929 (1993)
Terazosin
Titmarsh S and Monk JP
Drugs, 33(5), 461-477 (1987)
E Van Gyseghema et al.
Journal of chromatography. A, 1074(1-2), 117-131 (2005-06-09)
The starting point of this study was a current set of 32 chromatographic systems used to select initial conditions for method development to determine the impurity profile of a drug. The system exhibiting the best selectivity is then selected for
A G Ramage et al.
European journal of pharmacology, 294(2-3), 645-650 (1995-12-29)
The effects of i.v. infusion of the alpha1-adrenoceptor antagonists doxazosin and terazosin (2 mg kg-1 h-1) on spontaneous hypogastric, renal and inferior cardiac nerve activity, spontaneous bladder contractions, blood pressure, heart rate and femoral arterial flow were investigated separately in
E Van Gyseghem et al.
Journal of pharmaceutical and biomedical analysis, 41(1), 141-151 (2005-12-15)
Several chemometric techniques were compared for their performance to determine the orthogonality and similarity between chromatographic systems. Pearson's correlation coefficient (r) based color maps earlier were used to indicate selectivity differences between systems. These maps, in which the systems were
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique